Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Clorazepic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALB | P02768 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.65 |
| ▸ | CCKBR | P32239 | 4/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clorazepic Acid SCHEMBL34617 | 1.00 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL34618 | 1.00 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL29484725 | 1.00 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL27617141 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL1302660 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL9694061 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL4287456 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL236792 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL29374553 | 0.98 | LMNA (0.70) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL21462311 | 0.98 | LMNA (0.70) | LMNAMEN1ALBKMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3436000-B1 | USE OF CANNABINOIDS IN THE TREATMENT OF STURGE WEBER SYNDROME | JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) | 2025-07-16 | — | — | EP | claimed |
| US-20250205146-A1 | GRAPHENE-BASED DRUG DELIVERY DEVICE FOR MUCOSAL AND TRANSMUCOSAL ADMINISTRATION | SISSA - SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI (IT) | 2025-06-26 | — | — | US | claimed |
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| EP-4493150-A1 | GRAPHENE-BASED DRUG DELIVERY DEVICE FOR MUCOSAL AND TRANSMUCOSAL ADMINISTRATION | SISSA - Scuola Internazionale Superiore di Studi Avanzati (IT) | 2025-01-22 | — | — | EP | claimed |
| EP-4023222-B1 | NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATOR FOR TREATMENT OF 22Q SYNDROME | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2024-12-18 | — | — | EP | claimed |
| EP-3638673-B9 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-20 | — | — | EP | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-1558257-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2005-08-03 | — | — | EP | claimed |
| EP-1558221-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2005-08-03 | — | — | EP | claimed |
| US-20050152843-A1 | Abuse-proofed dosage form | GRUNENTHAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| EP-1515702-A1 | ABUSE-PROTECTED ADMINISTRATION FORM | Grünenthal GmbH (DE) | 2005-03-23 | — | — | EP | claimed |
| WO-2004075877-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | PHARMACEUTICAL PRODUCTIONS, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| WO-2004037259-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004037230-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2003105808-A1 | ABUSE-PROTECTED ADMINISTRATION FORM | Grünenthal GmbH (DE) | 2003-12-24 | — | — | WO | claimed |
| WO-2003004015-A1 | OIL-IN-WATER EMULSIONS COMPRISING A BENZODIAZEPINE DRUG | WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED (GB) | 2003-01-16 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |